Loading clinical trials...
Loading clinical trials...
Measurable-residual Disease (MRD) Monitoring of Nucleophosmin 1 (NPM1)-Mutated Acute Myeloid Leukaemia (AML) and Pre-emptive Therapy With Oral Arsenic Trioxide-based Regimen
Conditions
Interventions
Oral Arsenic Trioxide Formulation
Locations
1
Hong Kong
The University of Hong Kong
Hong Kong, Hong Kong
Start Date
January 1, 2021
Primary Completion Date
December 31, 2023
Completion Date
December 31, 2024
Last Updated
October 4, 2022
Lead Sponsor
The University of Hong Kong
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions